Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Clinical Trial Study Group Discusses Way to Lighten Sponsors' Burden
October 9, 2006
- CMIC Begins CRF Checking Services
October 9, 2006
- PMDA to More Closely Cooperate with Other Asian Countries: Mr Miyajima
October 9, 2006
- FTC Survey Faults New Drug Makers for Misleading Info. on Generics
October 9, 2006
- R&D NEWS IN BRIEF
October 9, 2006
- Expert Sees Legal Risk in Limited-Facility, All-case PMS
October 9, 2006
- MEDICAL DEVICE NEWS IN BRIEF
October 9, 2006
- Pros and Cons of All-Case PMS Presented: SJP Seminar
October 9, 2006
- NEW PRODUCTS
October 9, 2006
- BUSINESS NEWS IN BRIEF
October 9, 2006
- OPINION／Educating HQ
October 9, 2006
- STATISTICS
October 9, 2006
- Costs of Obligatory Stomach Cancer Exam Would Be Offset by Reduced Treatment Costs: Prof. Tsubono
October 9, 2006
- JGPMA Member Companies Post 9.2% Growth in Sales in FY2005
October 9, 2006
- Patients with Mild Ulcerative Colitis, Parkinson's Disease to Be Excluded from Subsidy
October 9, 2006
- SURVEY 3 articles
October 9, 2006
- Dr Takeyama Stresses Need to Educate Public about OAB
October 9, 2006
- TOPICS／Pfizer Commits US$15 Mil. to Protect African Children from Malaria
October 9, 2006
- Hakuo Yanigasawa Appointed Minister of Health
October 9, 2006
- New Head of METI to Push for Strong Economic Growth
October 9, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…